VectivBio acquires biotechnology company Comet Therapeutics. The advisors

VectivBio Holding, clinical-stage biopharmaceutical company specialising in novel transformational treatments for severe rare conditions announced the acquisition of Comet Therapeutics, a biotechnology company that has been developing drugs to address previously untreatable inherited metabolic diseases. This acquisition expands VectivBio’s rare disease pipeline. 

Homburger advises VectivBio Holding in this matter. The Homburger team includes parnter Andreas Müller (pictured) associates Margrit Marti, Angela Oppliger and Kevin Hubacher  (all corporate / m&a), partner Stefan Oesterhelt and associate Joël Gyger (both tax). 

VectivBio will acquire Comet Therapeutics in exchange for equity and cash payable at closing, as well as additional equity or cash payments upon the achievement of future development milestones. The transaction is expected to close by the end of September 2021, subject to customary closing conditions.